Pubdate: Sat, 12 Aug 2000 Source: Financial Times (UK) Copyright: The Financial Times Limited 2000 Contact: 1 Southwark Bridge, London, SE1 9HL, UK Fax: +44 171 873 3922 Website: http://www.ft.com Note: Part 4 of a 4 part series WORLD NEWS: THE AMERICAS: Dope wars: brain may hold key to addiction: Researchers are working on the theory that addiction is genetic and are hoping to find a marker that would identify those who are more susceptible to drug abuse and thus could be helped much sooner: Part IV: Can Science Win The Drugs War? PART IV: CAN SCIENCE WIN THE DRUGS WAR? Lynn Zimmer has tried, albeit unsuccessfully, to calculate exactly how many plastic vials of urine are airborne at any given moment en route to laboratories. Drug testing is a growth business in the US. According to one study, about half of all American workers under the age of 49 were tested for drug use by their employers in 1997, as companies enthusiastically joined America's war on drugs. Ms Zimmer, a Queens College, New York, sociologist who has studied the drug war for the last 10 years, says many companies - including courier services, test tube makers and airlines - now have stakes in the battle to eviscerate drug use. Science, also, is benefiting from federal funding. Researchers are studying the impact of drug use on the human body, the characteristics of users, and medicines to free addicts from their habits. Many scientists believe the key to understanding drug addiction is to be found in the human brain. The National Institute on Drug Abuse, which supervises the science front of the drug war, says 25 years of research has brought the agency to the cusp of new discoveries for causes, prevention and treatment of drug addiction. Research has yielded an understanding of molecular details of every abused drug and the action they exert on the body. Nida is receiving Dollars 690m in federal funding this year. It will award 12,000 research grants and fund a clinical trials network to determine which methods work best in treatment centres. Nida is not immune from criticism. "Nida never does a sober cost/benefit analysis of the drug war itself," said James Bovard, author of a new book, Feeling Your Pain, which dissects many of the drug programmes. Another critic is Marsha Rosenbaum, a former Nida researcher, now San Francisco director of Lindesmith Centre-Drug Policy Foundation, which opposes US drug policies. "We knew everything we needed to know about methadone," she says of the drug that is given to addicts in place of heroin. "But they kept funding studies anyway." Agency officials believe that soon they will prove a theory which treatment specialists have held for years: that addiction - or vulnerability to addiction - is genetic. Researchers hope to discover biological markers that would identify those who are more susceptible to drug abuse. Research discoveries are then used to develop new drugs that they hope will quench the desire for damaging and addictive illegal substances. "We started doing medication development 10 years ago when it was clear that the pharmaceutical industry wasn't interested in doing it," says Dr Tim Condon, Nida associate director. "There is a stigma associated with addiction and the attitude that 'They did this to themselves'." However, pharmaceutical cures rather than abstinence to kick the habit are controversial among many treatment providers, such as Michael Guiro, of a Phoenix House programme in New York. "The best way to go in the long run is a drug-free approach," he says. But the drug policy office in the White House has already concluded that drug use to combat drug addiction, is acceptable. "It should be approached like other chronic illnesses - such as diabetes and hypertension," the office said in its 2000 annual report. In a Nida brain-imaging centre in Baltimore, researchers are studying human and monkey brains to learn where drugs act, the neurotransmitter systems with which they act and the timing of the distribution of drugs in the body. "We are also studying how the brains of drug abusers act differently from nonabusers," Dr Alaine Kines says. She says some scientists think that drug abusers have "a problem" with the orbital frontal cortex in the underside of the brain. Ms Zimmer is less than impressed with the brain research. "I don't think it tells us much, nor is it clear what these pictures mean. They are bright and dramatic, but I don't think they answer the question of why some people take too many drugs and why some don't. "What if it can be determined who is likely to become an addict? I worry about the interventions that they will do. How do we know for sure if they are any good?" Nida has also set aside Dollars 54m for research on "party drugs", particularly ecstasy, for which demand is surging among young people. The science agency has already concluded that heavy ecstasy use could lead to impairment in other cognitive functions, such as the ability to reason verbally. But the research is preliminary, Ms Rosenbaum says, and the "exaggeration and hysteria" of the message just justifies more crackdowns and seizures by police. This, she worries, may bring on to the market look-alike drugs that are far more dangerous. The warnings are not frightening to millions of young people taking the drug, Ms Zimmer says. "They are not dropping like flies. They're having fun." It is difficult to bet against science, which has brought miracle cures for diseases all over the world. However critics charge that a silver-bullet cure is too easy and too close to taking drugs in the first place. If the scientists have it right, a pill could conquer the drug plague, and all the billions of dollars spent each year on military hardware, aerial spraying, imprisonment and even treatment could some day be saved. Drug-dependent businesses would go the way of the buggy whip. But it is not likely to happen soon. This is the last of a four-part series. All the articles can be seen at www.ft.com - --- MAP posted-by: Jo-D